Jorge Sierra

Research interests

Publications

• Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

  Blood · 2024 · https://doi.org/10.1182/blood.2024025409

• International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

  Blood · 2022 · https://doi.org/10.1182/blood.2022015850

• Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

  Blood · 2022 · https://doi.org/10.1182/blood.2021011583

• Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

  Blood · 2022 · https://doi.org/10.1182/blood.2022016867

• Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

  Blood · 2019 · https://doi.org/10.1182/blood.2019002697

• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1614359

• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

  Blood · 2016 · https://doi.org/10.1182/blood-2016-08-733196

• Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1506002

• Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

  Leukemia · 2015 · 10.1038/leu.2015.98

• Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

  Bone Marrow Transplantation · 2013 · https://doi.org/10.1038/bmt.2013.107

• Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

  Blood · 2013 · 10.1182/blood-2012-06-431122

• The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  Nature Reviews Clinical Oncology · 2012 · https://doi.org/10.1038/nrclinonc.2012.150

• Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.36.9868

• Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

  Haematologica · 2011 · 10.3324/haematol.2011.045757

• Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.4821

• Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.1900

• Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia

  Blood · 2009 · 10.1182/blood-2009-10-249128

• Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

  JAMA · 2009 · 10.1001/jama.2009.813

• Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-235358

• Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.1641

• Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses in Adult Recipients of Hematopoietic Stem Cell Transplants for Hematologic Malignancies

  Transplantation and Cellular Therapy · 2005 · 10.1016/j.bbmt.2005.07.007

• Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

  Annals of Oncology · 2005 · 10.1093/annonc/mdi119

• Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.

  PubMed · 2002

• Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

  Journal of Clinical Oncology · 2001 · 10.1200/jco.2001.19.5.1395

• Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.

  PubMed · 2001

• Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience

  Bone Marrow Transplantation · 2000 · 10.1038/sj.bmt.1702519

• Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose

  Blood · 1997 · 10.1182/blood.v89.11.4226

Current projects

No projects listed.